Heparina Galenika

Heparina Galenika is a prescription injectable solution containing the anticoagulant heparin. It is supplied in an unspecified strength for intravenous administration and is marketed in the European Union. The product belongs to the antithrombotic drug class and works by enhancing antithrombin III activity to inhibit clotting factors. It is used under medical supervision for preventing and treating thromboembolic conditions, including deep vein thrombosis and pulmonary embolism.

Heparina Galenika is indicated for several clinical situations where anticoagulation is required.

- Prevention and treatment of deep vein thrombosis (DVT) - Prevention and treatment of pulmonary embolism (PE) - Anticoagulation during cardiac surgery, coronary artery bypass grafting, and hemodialysis - Prevention of clot formation in arterial and venous grafts - Management of acute thrombotic events when rapid anticoagulation is needed

Adverse reactions to Heparina Galenika vary in frequency and severity.

Common: - Minor bleeding at injection site - Hematuria (blood in urine) - Epistaxis (nosebleeds) - Bruising or hematoma formation - Elevated liver enzymes (transient)

Serious: - Major hemorrhage (intracranial or gastrointestinal) - Heparin-induced thrombocytopenia (HIT) - Allergic reactions including anaphylaxis - Spontaneous spinal or epidural hematoma

Before initiating Heparina Galenika, clinicians should evaluate several safety considerations.

- Assess baseline coagulation parameters and platelet count - Review patient history for recent surgery, trauma, or active bleeding - Use with caution in renal or hepatic impairment - Avoid in patients with known hypersensitivity to heparin or pork-derived products - Monitor for signs of heparin-induced thrombocytopenia during therapy - Adjust dose in pregnancy (Category B) only under specialist guidance

Heparina Galenika may interact with other agents that affect hemostasis or drug metabolism.

Avoid: - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring - Antiplatelet drugs such as aspirin, clopidogrel, or NSAIDs that increase bleeding risk - Thrombolytic agents (e.g., alteplase) during the same treatment period

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may potentiate bleeding - Certain antibiotics (e.g., quinolones) that can enhance anticoagulant effect - High‑dose corticosteroids that may affect platelet function